Medicine
Volume 36, Issue 7 , Pages 355-359 , July 2008

Drug metabolism

References 

  1. Park BE, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol. 1998;11:969–988
  2. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet. 2002;360:1155–1162
  3. Delco F, Tchambaz L, Schlienger R, Drewe J, Krahenbuhl S. Dose adjustment in patients with liver disease. Drug Saf. 2005;28:529–545
  4. Thummel KE. Gut instincts: CYP3A4 and intestinal drug metabolism. J Clin Invest. 2007;117:3173–3176
  5. Baron JM, Holler D, Schiffer R, et al. Expression of multiple cytochrome P450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. J Invest Derm. 2001;116:541–548
  6. Pirmohamed M, Orme MLE. Drug interactions of clinical importance. In:  Davies DM,  Ferner RE,  de Glanville H editor. Textbook of adverse drug reactions. London: Chapman & Hall; 1998;p. 888–912
  7. Mannel M. Drug interactions with St John’s wort: mechanisms and clinical implications. Drug Saf. 2004;27:773–797
  8. Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet. 1997;33:103–121
  9. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15–19
  10. Pirmohamed M, Park BK. Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology. 2003;192:23–32
  11. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116:496–526
  12. Borges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006;80:61–74
  13. Innocenti F, Ratain MJ. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics. 2006;7:1211–1221
  14. Park K, Williams DP, Naisbitt DJ, Kitteringham NR, Pirmohamed M. Investigation of toxic metabolites during drug development. Toxicol Appl Pharmacol. 2005;207(suppl 2):425–434
  15. Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis. 2007;11:525–548

PII: S1357-3039(08)00111-4

doi: 10.1016/j.mpmed.2008.04.002

Medicine
Volume 36, Issue 7 , Pages 355-359 , July 2008

Article Tools

* Image Usage & Resolution